EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation

The optimal treatment for EGFR-mutated NSCLC is still an open issue. EGFR-TKIs combined with anti-angiogenic drugs can bring short-term efficacy, but not benefit long-term survival and instead increase adverse reactions (AEs). The short-term efficacy of EGFR-TKIs combined with chemotherapy is clear, but the long-term efficacy varies in different studies, with significant benefits in certain subgroups. EGFR-TKIs combined with immune checkpoint inhibitors (ICIs) show a trend toward efficacy benefit; however, their high AEs require further optimization of the combination regimen.